Entrada Results, Updates

  Cash runway extended through the second quarter of 2026 –

– $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 –

– Completed dosing for third cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for the second half of 2024 –

– Regulatory applications expected in the fourth quarter of 2024 for the global Phase 2 clinical development of ENTR-601-44 and ENTR-601-45 in people living with DMD –

https://www.globenewswire.com/news-release/2024/03/13/2845281/0/en/Entrada-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html